BPC-157 vs TB-500
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, gastroprotection, and tendon/ligament/muscle healing. Important: essentially all efficacy data are preclinical (rodent), there are no completed published human efficacy trials, and it is prohibited in sport by WADA.
Full profileTB-500
TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous protein involved in cell migration, tissue repair, and inflammation regulation. It has shown significant healing properties in preclinical models across muscle, tendon, ligament, and cardiac tissue.
Full profile| BPC-157 | TB-500 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157 | Thymosin Beta-4, Tβ4, TB500 |
| Evidence | Preclinical only | Preclinical only |
| Dosing range | 200mcg–1000mcg mcg, once or twice daily | 2mg–10mg mg, twice weekly (loading), weekly (maintenance) |
| Administration | Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols) | Subcutaneous injection, Intramuscular injection |
| Key side effects | Nausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trials | Head rush / lightheadedness (transient), Lethargy at higher doses, Injection site discomfort, Nausea (rare) |
| Cited sources | 6 references | 2 references |
Key differences
- Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); TB-500 — Subcutaneous injection, Intramuscular injection.
- Dosing units differ: BPC-157 is dosed in mcg, TB-500 in mg — they operate at different scales.
- Frequency: BPC-157 is typically once or twice daily; TB-500 is twice weekly (loading), weekly (maintenance).
- Research depth: this profile cites 6 sources for BPC-157 vs 2 for TB-500.
Can you stack BPC-157 and TB-500?
synergistic: Classic healing stack — highly complementary
BPC-157 and TB-500 are the most widely researched healing combination. BPC-157 drives angiogenesis and growth factor signaling; TB-500 regulates actin polymerization and cell migration. They work on different pathways and are commonly combined for tendon, ligament, and gut repair protocols.
See the full compatibility matrixHow each works
BPC-157
Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.
TB-500
TB-500 promotes healing by upregulating actin, which drives cell migration to injury sites. Animal studies show accelerated repair of muscle tears, tendon injuries, and corneal wounds. It also demonstrates anti-inflammatory properties and has been studied for cardiac tissue repair following ischemic injury.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.